Pharma player Alembic Pharmaceuticals Limited on Tuesday posted standalone net profit at ₹277 crore for the quarter ended December 31, 2020, which is about 19 per cent higher than ₹233 crore reported in the corresponding quarter last year.
The company’s standalone revenues from operations stood at ₹1,236 crore for the quarter as against ₹1,052 crore in the same period last year.
On a consolidated basis, the company posted net profit of ₹293 crore for the quarter ended December 2020, which is about 25 per cent higher than ₹234 crore reported in the corresponding quarter last year.
Consolidated revenues from operations was reported at ₹1,314 crore, up from ₹1209 crore recorded in the same period last year.
‘A good quarter’
Pranav Amin, Managing Director, Alembic Pharmaceuticals, said: “It was another good quarter for the company led by strong growth in the India formulation business. The API Business continued to perform well in current quarter.”
The company said in a statement that its international formulations business grew by 3 per cent to ₹683 crore during the quarter and 27 per cent to ₹2,233 crore for the nine-month ended December 2020.
Ex-US International Formulations business grew by 14 per cent to ₹171 crore in the quarter and 49 per cent to ₹544 crore for April-December 2020.
India formulations business grew 14 per cent to ₹418 crore in the quarter and 5 per cent to ₹1,138 crore for the nine-month period.
The company’s specialty segments grew by 16 per cent for the quarter led by Cardio, Diabeto, Gyanaec and Gastro Segments, it said, adding that the API business reported a growth of 21 per cent to ₹214 crore during the quarter and 34 per cent to ₹741 crore for the nine-month period.
Alembic Pharmaceuticals shares traded nearly flat with marginal decline at ₹1,063 on Tuesday, down 0.6 per cent over previous close on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.